OUTSPOKEN ONCOLOGY

Episode 45: Simplifying Biosimilars With Gary Lyman

05/03/2022

Gary Lyman, MD, MPH, senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice, as well as delves into issues of granting extrapolation.

To watch Chadi discuss biosimilars at the most recent ASH Annual Meeting & Exposition, click here.

To watch Dr Lyman discuss biosimilars at the 2018 ASCO Annual Meeting, click here.

Dr Nabhan and Dr Lyman have no relevant financial disclosures.

Current Issue

August 2024

Volume 10

Issue 4

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

News

Impact of New York State's Medicaid MLTC Program on Nursing Home Use Among Older Adults With Dementia

09/19/2024

Hannah Musick ;

A study in JAMA Network Open reveals that New York State's Medicaid-managed long-term care program has decreased nursing home use among older adults with dementia, offering a potential solution to manage costs and improve consumer choice.

A study in JAMA Network Open...

09/19/2024

Journal of Clinical Pathways

Conference Coverage

CPC + CBEx 2024: Integration of Medical Oncology and Surgical Specialties

09/19/2024

Grace Taylor , MS, MA;

Presenters at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange shared how their institutions integrate medical oncology and surgical specialties for genitourinary cancers and some of the challenges they face both clinically...

Presenters at the 2024 Clinical...

09/19/2024

Journal of Clinical Pathways

Conference Coverage

CPC + CBEx 2024: Pathways for Social Needs Assessment and Care

09/18/2024

In a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange, experts went over the importance of social needs assessment and care in oncology and provided an example of pathways that help in providing these services to...

In a session at the 2024...

09/18/2024

Journal of Clinical Pathways

Videos

Evaluating Stereotactic Radio Surgery Plus TKI Vs TKI Alone Among Patients With Brain Metastases from EGFR- and ALK-Altered NSCLC (Part II)

09/18/2024

Luke R.G. Pike , MD, PhD;

Luke Pike, MD, shares key takeaways from the TURBO-Non–Small Cell Lung Cancer study and highlights promising studies on the horizon for EGFR mutant NSCLC treatment.

Luke Pike, MD, shares key...

09/18/2024

Journal of Clinical Pathways

News

Pembrolizumab May Improve Disease-Free Survival in Patients With High-Risk Endometrial Cancer

09/17/2024

Hannah Musick ;

Adding pembrolizumab to adjuvant chemotherapy improves disease-free survival in women with high-risk endometrial cancer, particularly those with mismatch repair-deficient tumors, according to findings from the KEYNOTE-B-21 study presented at...

Adding pembrolizumab to adjuvant...

09/17/2024

Journal of Clinical Pathways

Episode 45: Simplifying Biosimilars With Gary Lyman

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products